Navigation Links
FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade

CF Foundation's $1 Million Investment Helped Drug Known as Cayston(R) Become a Reality

BETHESDA, Md., Feb. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

Developed by Gilead Sciences, Inc., Cayston offers a much-needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics. Lung infections are the leading cause of death in CF.

Cayston is the first CF drug to advance — from beginning to end — through the Cystic Fibrosis Foundation's Therapeutics Development Program, which is designed to speed the creation of new CF therapies. In addition, Cystic Fibrosis Services, Inc, a wholly owned subsidiary of the Foundation, will be one of only several pharmacies in the country distributing the drug.

Cayston will be available by the end of next week.

"The approval of Cayston demonstrates that our drug development model is working and making a real difference in the lives of people with cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "We are delighted to have a new antibiotic in the arsenal to help fight the life-threatening infections associated with this disease, as we continue to push forward with other therapies that address the underlying cause of CF."

The Foundation supported Cayston at each stage of development, from providing an initial therapeutics development award, to making the Foundation's clinical trials network available to test the drug in patients, to advocating with the FDA for the drug's approval.

"The Cystic Fibrosis Foundation's early funding and ongoing support for Cayston played an important role in bringing this new therapy to patients," said Bruce Montgomery, M.D., senior vice president, head of Respiratory Therapeutics, Gilead Sciences. "We are thrilled to help meet an urgent medical need for CF patients, and to support the Foundation's mission to improve the lives of people with this terrible disease."

Cayston is administered with a new device called the Altera(R) Nebulizer System that allows patients to take the medicine in less than five minutes, a fraction of the time required for other inhaled antibiotics. This shortened delivery time reduces the burden on patients, who – on average – have a treatment regimen of three-to-four hours per day.  

Patients interested in learning more about Cayston should consult their physicians.

To support patients, Gilead is launching a Cayston Access Program, a call center developed with a nonprofit subsidiary of the Cystic Fibrosis Foundation.

The program will assist people with CF and members of their care team with insurance verification, co-pay assistance and claims support. For information, call 1-877-7CAYSTON (877-722-9786).

In 2004 Cystic Fibrosis Foundation Therapeutics, Inc., a nonprofit affiliate of the Cystic Fibrosis Foundation, gave a therapeutics development award to Corus Pharma to support an experimental drug now known as Cayston. In 2006, Gilead Sciences acquired Corus and continued the program, filing a New Drug Application with the FDA in 2007.  

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. For more information, please visit

SOURCE Cystic Fibrosis Foundation

Back to top



SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
2. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
3. FDA Approves Xiaflex for Debilitating Hand Condition
4. FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
5. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
6. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
7. FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
8. FDA Approves Lillys ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
9. FDA Approves Lillys Zyprexa for Two Adolescent Indications
10. US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
11. FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
Breaking Medicine Technology:
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
Breaking Medicine News(10 mins):